INC Research/inVentiv Health Awarded SCRS Eagle Award
INC Research/inventive Health, biopharmaceutical solutions organization combining CRO and CCO (Contract Commercial Organization), announced it was awarded the 2017 Society for Clinical Research Sites (SCRS) Eagle Award in the CRO category during the SCRS Annual Global Site Solutions Summit held earlier this month.
The award recognizes the CRO that best exemplifies leadership, professionalism, integrity, passion, and dedication to advancing clinical research through strong site partnerships. Finalists were selected by nominations from SCRS members-nearly 9,000 research sites in 45 countries. Selection criteria included availability of qualified staff to support sites, willingness to collaborate, protocol design and execution, financial consideration and partnering with sites for future work. CROs that ranked in the 75th percentile or above in the initial round of voting were then moved to a final ballot. All sites, regardless of SCRS membership, were able to select a winner for announcement at the Summit.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
